Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746753 · ClinicalTrials.gov registry record · Phase 4
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
NCT06746753 is a Phase 4 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 78 participants.
The verdict
NCT06746753, a Phase 4 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
Study Summary
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Interventions
- DRUG Norepinephrine
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-10-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06746753
The ClinicalTrials.gov registry entry for NCT06746753 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Norepinephrine is the first listed.
NCT06746753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06746753 about?
NCT06746753 is a clinical study titled "Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock". Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are...
What is the current status of trial NCT06746753?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2026-07. Estimated completion is 2028-10-07.
What interventions are being tested in trial NCT06746753?
The interventions under investigation include: Norepinephrine (DRUG), Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT06746753?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.